Frequency Therapeutics CEO David Lucchino (L) and Korro Bio CEO Ram Aiyar
July 14, 2023 06:54 AM EDTUpdated 09:45 AM
Startups
Deals

Fre­quen­cy to hand Nas­daq spot to Ko­r­ro Bio as At­las-found­ed RNA edit­ing start­up nabs $117M

Kyle LaHucik

Senior Reporter

Re­verse merg­ers are in vogue, and Fre­quen­cy Ther­a­peu­tics will join the bo­nan­za, with RNA edit­ing start­up Ko­r­ro Bio ex­pect­ed to take its spot on the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J takes 340B fight with fed­er­al gov­ern­ment to court

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times